PRECIGEN, INC. PGEN
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including AdenoVerse immunotherapy, and UltraCAR-T, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M | $32.0M | $90.7M | $151.2M | $219.5M | $190.9M |
| Cost of revenue | — | — | — | — | — | — | — | — | $29.5M | $23.9M |
| Gross profit | — | — | — | — | — | — | — | — | $189.9M | $167.0M |
| R&D | $41.3M | $53.1M | $48.6M | — | — | — | — | $404.6M | $143.2M | $112.1M |
| SG&A | $70.1M | $41.3M | $40.4M | — | — | — | — | $137.8M | $146.1M | $142.3M |
| Total operating expenses | $120.2M | $139.0M | $106.0M | — | — | — | — | $666.2M | $368.9M | $316.1M |
| Operating income | -$110.5M | -$135.0M | -$99.8M | — | — | — | — | -$505.6M | -$137.9M | -$125.2M |
| Interest expense | $3.9M | $6.0K | $468.0K | — | — | — | — | $8.5M | $611.0K | $861.0K |
| Pre-tax income | -$250.6M | -$128.0M | -$96.4M | -$80.0M | -$111.0M | -$104.5M | -$171.3M | -$395.9M | -$78.4M | -$194.2M |
| Income tax | $3.0K | $1.8M | $458.0K | $189.0K | $160.0K | $82.0K | $930.0K | $15.4M | $2.1M | $3.9M |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M | -$92.2M | -$170.5M | -$322.3M | -$509.3M | -$117.0M | -$186.6M |
| EPS, basic | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | — | — | — |
| EPS, diluted | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | -3.93 | -0.98 | -1.58 |
| Shares, diluted (wtd. avg.) | $313.0M | $267.7M | $244.5M | $200.4M | $197.8M | $167.1M | $154.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.2M | $29.5M | $7.8M | $48.6M | $43.3M | $52.2M | $68.4M | $110.2M | $75.5M | $69.6M |
| Short-term investments | $67.6M | $68.4M | $55.3M | $51.1M | $72.2M | $48.3M | $9.3M | $119.6M | $6.3M | $174.6M |
| Receivables | $3.9M | $926.0K | $902.0K | $978.0K | $1.3M | $16.5M | $20.6M | $21.2M | $19.8M | $21.6M |
| Total current assets | $115.2M | $102.4M | $68.8M | $118.2M | $156.6M | $148.9M | $234.6M | $285.5M | $154.0M | $315.2M |
| Property, plant and equipment | $13.8M | $13.8M | $7.1M | $7.3M | $8.6M | $34.9M | $44.0M | $86.9M | $112.7M | $64.7M |
| Goodwill | $15.2M | $19.1M | $26.6M | $36.9M | $37.6M | $54.4M | $54.1M | $93.6M | $93.8M | $157.2M |
| Other intangibles | $3.2M | $4.5M | $40.7M | $44.5M | $52.3M | $65.4M | $68.3M | $89.0M | $232.9M | $225.6M |
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M | $314.6M | $455.8M | $716.2M | $846.9M | $949.1M |
| Accounts payable | $12.0M | $3.5M | $1.7M | $4.1M | $3.1M | $4.6M | $5.5M | $12.0M | $8.7M | $8.5M |
| Short-term debt | — | — | $0 | $43.2M | $52.0K | $360.0K | $31.7M | $479.0K | $502.0K | $386.0K |
| Total current liabilities | $37.3M | $21.5M | $23.0M | $78.6M | $34.6M | $42.1M | $122.9M | $61.6M | $80.2M | $94.6M |
| Long-term debt | $93.2M | $0 | — | $0 | $179.9M | $171.5M | $186.3M | $211.2M | $7.5M | $7.6M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M | $247.4M | $384.1M | $337.5M | $300.3M | $379.8M |
| Retained earnings | -$2.34B | -$2.09B | -$1.96B | -$1.87B | -$1.92B | -$1.82B | -$1.65B | -$1.33B | -$847.8M | -$729.3M |
| Total equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M | $67.2M | $71.7M | $378.7M | $546.5M | $569.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M | -$55.8M | -$77.0M | -$135.9M | -$124.2M | -$103.7M | -$49.0M |
| Depreciation and amortisation | $3.2M | $4.5M | $6.7M | $10.8M | $13.8M | $17.5M | $24.9M | $33.1M | $31.1M | $24.6M |
| Stock-based compensation | $10.9M | $9.5M | $9.9M | $10.2M | $13.9M | $18.4M | $18.9M | $36.3M | $41.6M | $42.2M |
| Capital expenditure | $2.0M | $8.6M | $1.5M | $4.9M | $7.2M | $7.5M | $37.9M | $41.6M | $46.7M | $31.6M |
| Investing cash flow | -$1.5M | -$20.7M | -$3.1M | $226.4M | -$74.5M | $27.8M | $86.9M | -$151.2M | $104.3M | -$28.4M |
| Financing cash flow | $90.0M | $110.6M | $29.6M | -$155.3M | $121.2M | $32.7M | $8.1M | $309.8M | $4.3M | $12.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-018214.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |